地舒单抗治疗骨巨细胞瘤的卫生技术评估(7)
[23] RUTKOWSKI P,FERRARI S,GRIMER RJ,et al. Surgical downstaging in an open-label phase Ⅱ trial of denosumab in patients with giant cell tumor of bone[J]. Ann Surg Oncol,2015,22(9):2860-2868.
[24] BRANSTETTER DG,NELSON SD,MANIVEL JC,et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone[J]. Clin Cancer Res,2012,18(16):4415-4424.
[25] CAMPANACCI L,SAMBRI A,MEDELLIN MR,et al. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities[J]. Acta Orthop Traumato,2019,53(5):376-380.
[26] RUTKOWSKI P,GASTON L,BORKOWSKA A,et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone-multicenter analysis outside clinical trial[J]. EJSO,2018,44(9):1384-1390.
[27] ZOU C,LIN T,WANG B,et al. Managements of giant cell tumor within the distal radius:a retrospective study of 58 cases from a single center[J]. J Bone Oncol,2019. DOI:10.1016/j.jbo.2018.100211.
[28] 國家药品监督管理局药品审评中心.地舒单抗注射液申请上市技术评审报告[R]. 2019-10.
[29] BIERMANN JS,CHOW W,REED DR,et al. NCCN guidelines insights:bone cancer,version 2:2017[J]. J Natl Compr Canc Netw,2017. DOI:10.6004/jnccn.2017.0017.
(收稿日期:2020-04-29 修回日期:2020-06-18)
(编辑:孙 冰), http://www.100md.com(芮明军 唐文熙 李洪超)
[24] BRANSTETTER DG,NELSON SD,MANIVEL JC,et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone[J]. Clin Cancer Res,2012,18(16):4415-4424.
[25] CAMPANACCI L,SAMBRI A,MEDELLIN MR,et al. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities[J]. Acta Orthop Traumato,2019,53(5):376-380.
[26] RUTKOWSKI P,GASTON L,BORKOWSKA A,et al. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone-multicenter analysis outside clinical trial[J]. EJSO,2018,44(9):1384-1390.
[27] ZOU C,LIN T,WANG B,et al. Managements of giant cell tumor within the distal radius:a retrospective study of 58 cases from a single center[J]. J Bone Oncol,2019. DOI:10.1016/j.jbo.2018.100211.
[28] 國家药品监督管理局药品审评中心.地舒单抗注射液申请上市技术评审报告[R]. 2019-10.
[29] BIERMANN JS,CHOW W,REED DR,et al. NCCN guidelines insights:bone cancer,version 2:2017[J]. J Natl Compr Canc Netw,2017. DOI:10.6004/jnccn.2017.0017.
(收稿日期:2020-04-29 修回日期:2020-06-18)
(编辑:孙 冰), http://www.100md.com(芮明军 唐文熙 李洪超)